Retirement Guys Formula LLC Has $1.26 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Retirement Guys Formula LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 28.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,619 shares of the company’s stock after buying an additional 1,698 shares during the period. Retirement Guys Formula LLC’s holdings in Johnson & Johnson were worth $1,263,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JNJ. Lantz Financial LLC boosted its position in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $453,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after purchasing an additional 90 shares in the last quarter. State of Wyoming increased its stake in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after buying an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC increased its stake in Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after buying an additional 2,529 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $152.33 on Thursday. The company’s 50-day moving average price is $153.95 and its two-hundred day moving average price is $153.67. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market cap of $366.52 billion, a P/E ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Wall Street Zen raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.